A recent study published in the journal Communications Medicine reveals troubling trends in the representation of racial and ethnic minorities in clinical trials used for FDA drug approvals. The findings indicate that only 6% of these trials adequately reflect the racial and ethnic diversity of the United States. Alarmingly, there has been a noticeable decline in the participation of Black and Hispanic individuals since 2021, even as there have been simultaneous calls for greater equity within science and medicine.

Overview of the Study

Researchers from the University of California, Riverside, and University of California, Irvine, analyzed data from 341 pivotal trials conducted between 2017 and 2023. These trials are critical as they represent the final stage of testing before a drug can be approved for public use. Their findings illuminate a concerning trend in which both Black and Hispanic representation has declined, while participation among Asian individuals increased and White participation remained largely stable.

Implications of Underrepresentation

According to Sophie Zaaijer, a geneticist involved in the study, the implications of these findings are significant. "Precision medicine relies on understanding how genetic differences influence treatment outcomes," she stated. The lack of diversity in clinical trials could mean that vital information regarding the safety and efficacy of new drugs may be overlooked. Furthermore, variations among populations concerning gene versions, known as alleles, could greatly affect drug metabolism and responses.

Geographic Concentration and Its Consequences

In addition to the concerning representation of minorities, the geographic concentration of clinical trials also presents challenges. Most pivotal trials are conducted in locations such as the U.S., Europe, China, and Japan—regions that do not accurately reflect global genetic diversity. Alarmingly, many regions in Latin America host less than 3% of these trials. This geographic bias can inhibit the development of effective medications tailored to diverse populations.

Encouragingly, recent efforts have seen countries like Brazil, Mexico, and Argentina join the International Council for Harmonization (ICH), which may facilitate future trials that capture broader genetic variations, particularly for Hispanic populations.

Historical Context and Genetic Parallels

Zaaijer's research into this subject began during her postdoctoral fellowship at Cornell Tech, where she noted the skewed representation of genetic diversity in preclinical models. This bias, she argues, manifests in clinical trials and can ultimately affect medical practices. Zaaijer collaborated with Simon "Niels" Groen from UCR, who studies the genetic parallels between humans and organisms like tiny worms, which serve as models for understanding drug metabolism. Groen stated, "Many of the same genes used to break down chemicals in worms are also involved in drug metabolism in humans," emphasizing the importance of genetic study across different populations.

Recommendations for Enhancing Trial Diversity

The authors of the study provide several recommendations to improve diversity in clinical trials:

  • Set Diversity Goals: Establish diversity objectives at the outset of the drug development pipeline during the preclinical stage.
  • Choose Testing Locations Wisely: Select trial locations that represent the health needs and genetic backgrounds of the surrounding communities.
  • Collect Biological Samples: Gather relevant biological samples that can help researchers comprehend how diverse populations react to specific drugs.

As DNA testing becomes more commonplace in clinical settings, researchers underscore the need for comprehensive, ancestry-aware data to enable the full potential of personalized medicine. Groen asserted, "Precision medicine becomes possible only when clinical trials map the biology of all patients, not just a subset."

Conclusion

The shortcomings revealed by this study point to a crucial need for transformation in how clinical trials are conducted. By ensuring that diverse populations are represented in drug development, the medical community can improve the safety and effectiveness of new treatments for everyone. The journey towards inclusive and equitable medicine requires intentional efforts and structural changes in clinical research practices.

Further Information

For additional insights, refer to the article by Sophie Zaaijer et al., titled Longitudinal clinical trial enrollment trends across 341 US FDA-approved drugs and their guiding role in precision medicine strategies published in Communications Medicine in December 2025.

Additional Resources

Read more about the study and its implications at Medical Xpress.